Abstract
The considerable prevalence of asymptomatic hyperuricemia (HU) in the general population underscores the need for an in-depth investigation into its impact on the progression of various diseases, including rheumatological and comorbid conditions. This literature review elucidates the association between HU and systemic lupus erythematosus (SLE) and examines the pathogenetic and clinical foundations for implementing urate-lowering therapy in individuals with concurrent HU and SLE. It has been demonstrated that elevated serum uric acid (UA) levels correlate with an increased risk of pulmonary hypertension, stroke, arterial hypertension, hyperlipidemia, and metabolic syndrome. The mechanisms through which HU contributes to renal damage are explored independently, highlighting the challenges in ascertaining the primary etiology of renal disorder. Although direct interventional studies validating the necessity of urate-lowering therapy in patients with SLE, HU, and comorbidities (particularly cardiovascular diseases) are not currently available, there is substantial evidence supporting the beneficial impact of UA level normalization on cardiovascular outcomes. Given the negative impact of elevated UA levels on comorbid conditions that crucially influence the life expectancy of SLE patients (such as cardiovascular disease and chronic kidney disease), lifelong management of UA levels is advisable for individuals with SLE. KEYWORDS: systemic lupus erythematosus, hyperuricemia, comorbidity, metabolic syndrome, comorbid conditions, urate-lowering therapy. FOR CITATION: Musiychuk M.M., Gaydukova I.Z., Inamova O.V., Aparkina A.V., Rebrov A.P. Asymptomatic hyperuricemia effect on the course, outcomes and comorbid conditions in systemic lupus erythematosus. Modern view of the problem. Russian Medical Inquiry. 2024;8(7):391–399 (in Russ.). DOI: 10.32364/2587-6821-2024-8-7-4.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call